Avastin maintenance for a non-small cell lung cancer – pro
The ESMO 2016 guideline says: “three studies, one employing bevacizumab and the other two using monoclonal antibodies against EGFR (cetuximab or necitumumab) administered concomitantly to chemotherapy and further continued as monotherapy until disease progression, have demonstrated survival benefits, but the specific role of the maintenance phase cannot be appreciated in this context “.
However, NCCN in a footnote on p. NSCL-J, 2, writes that Bevacizumab should be given as a single agent, unless as maintenance therapy if initially used with chemotherapy.”
S. Novello F. Barlesi R. Califano T. Cufer S. Ekman M. Giaj Levra K. Kerr S. Popat M. Reck S. Senan, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of Oncology, Volume 27, Issue suppl_5, 1 September 2016, Pages v1–v27
NCCN, NSCL 2018